- On Monday, the Supreme Court followed the Solicitor General’s advice and denied certiorari in Joblove v. Barr Labs, which concerned the legality of a "reverse payment" settlement of Hatch-Waxman litigation. Last year, the Court denied certiorari in a similar case, FTC v. Schering. Dow Jones reports that the FTC has vowed to press forward in its campaign against reverse payment settlements.
- Synthon and Teva announced this week that the FDA granted final approval to their ANDAs for generic Norvasc (amlodipine besylate). They join Mylan, which launched in March, and Apotex, which launched in May.
- FDA Law Blog reported earlier this week on an interesting new paper examining the regulatory challenges facing drug/device combination products.
Recent Posts
- Hikma v. Vanda: Oral Argument Recap
- Teva v. Lilly should not be read as creating a new 112 rule for method of use claims
- Should ANDA filers be using the PTAB to mount early challenges to OB patents?
- Switching to WordPress
- Judge Hughes concurrence highlights post grant review appeal standing issue for pharma cases
Orange Book Blog 
Leave a comment